Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Japan ETF (EWJ) vs Medpace Holdings Inc (MEDP) Price & Performance

iShares MSCI Japan ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Japan ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI Japan ETF trades at $97.7, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.

EWJMEDP
Sector
Broad Market / FactorTechnology
52-Week High
$96.97$620.59
52-Week Low
$77.93$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Japan ETF

EWJ, the iShares MSCI Japan ETF, trades at $97.68, up 1.7% on the day, with a bullish technical signal driven by moving averages. The ETF's performance is influenced by Japan's economic policies, including recent U.S.-Japan yen intervention and domestic stimulus efforts. Key support sits at $96, while resistance is at $97, with the RSI indicating potential overbought conditions.

Outlook remains tied to Japan's economic reforms and currency stability, offering exposure to Japanese equities but with risks from yen volatility and inflation. Investor sentiment is cautious amid BOJ policy uncertainty, though institutional interest persists for diversification benefits.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Japan ETF

EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.

Read more on EWJ

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP